This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Atara Biotherapeutics Schedules FDA...
Regulatory FDA meeting

Atara Biotherapeutics Schedules FDA Meeting for Tabelecleucel

Analysis based on 10 articles · First reported Mar 03, 2026 · Last updated Mar 12, 2026

Sentiment
20
Attention
2
Articles
10
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The market is positively impacted by the scheduled Type A meeting between Atara Biotherapeutics' partner, Pierre Fabre Pharmaceuticals, and the United States===Food and Drug Administration. This indicates progress towards addressing the Complete Response Letter for Tabelecleucel, potentially leading to future market approval and increased revenue for Atara Biotherapeutics.

Biotechnology Pharmaceuticals
Event Summary

Atara Biotherapeutics announced that a Type A meeting with the U.S. United States===Food and Drug Administration has been scheduled to discuss the Complete Response Letter for tabelecleucel (tab-cel). Pierre Fabre Pharmaceuticals, Atara's partner, will meet with the agency to address the points from the CRL and enable a resubmission with additional efficacy data. Cokey Nguyen, President and CEO of Atara, expressed optimism about gaining clarity on the path forward for resubmission. Atara Biotherapeutics is a leader in T-cell immunotherapy, developing therapies for cancer and autoimmune diseases. They anticipate providing a regulatory update in the second quarter.

Key Actions
90 United States===Food and Drug Administration granted Type A meeting Pierre Fabre Pharmaceuticals
90 Atara Biotherapeutics scheduled Type A meeting with United States===Food and Drug Administration United States===Food and Drug Administration
80 United States===Food and Drug Administration issued Complete Response Letter for Tabelecleucel Atara Biotherapeutics
Entities Involved
stock
Atara Biotherapeutics
Atara Biotherapeutics is a leader in T-cell immunotherapy and is developing transformative therapies for patients with cancer and autoimmune diseases. The scheduled Type A meeting with the FDA to discuss the Complete Response Letter for tabelecleucel is a positive step towards potential market approval, which could significantly benefit the company.
Importance 90 Sentiment 20
priv
Pierre Fabre Pharmaceuticals
Pierre Fabre Pharmaceuticals is Atara Biotherapeutics' partner for tabelecleucel. They will be meeting with the FDA to address the points from the Complete Response Letter, aiming for a resubmission of the Biologics License Application.
Importance 80 Sentiment 20
govactor
United States===Food and Drug Administration
The United States===Food and Drug Administration is the regulatory body that issued a Complete Response Letter for tabelecleucel. They have granted a Type A meeting to Pierre Fabre Pharmaceuticals to discuss the path forward for resubmission.
Importance 70 Sentiment 0
Relationships
Atara Biotherapeutics related ↔ Pierre Fabre Pharmaceuticals
United States===Food and Drug Administration related ↔ Atara Biotherapeutics
Pierre Fabre Pharmaceuticals related ↔ United States===Food and Drug Administration
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.